{arrow_up} Back to top

Risk Minimisation Materials

Search by company, common medicine name, or title of Risk Minimisation Material

Darzalex

Janssen-Cilag Ltd

{pdf_link}

HCPs-_Important information on safety and risk minimisation of Daratumumab and interference with Blood Compatability Testing

{healthcare_pro_orange} For Healthcare Professionals

Inform health care professionals of the interference of Darzalex (daratumumab) with antibody screening and crossmatching


{pdf_link}

Important Information about Blood Transfusions

Card for patient's receiving Darzalex (daratumumab)- patient should carry this card while receiving treatment and for 6 months after treatment has ended.


{pdf_link}

Important information on safety and risk minimisation of Daratumumab and Interference with Blood Compatibility Testing

{healthcare_pro_orange} For Healthcare Professionals

Information for Blood Banks on the intereference with Antiglobulin Test _blood typing


Daurismo

Pfizer Limited

{pdf_link}

Daurismo (glasdegib) Patient Alert Card

Patient alert card for male patients regarding the risk of embryo-foetal risks of exposure to women of child-bearing potential by semen associated with DAURISMO


Deferasirox

Teva UK Limited

{pdf_link}

Deferasirox HCP Information Brochure

{healthcare_pro_orange} For Healthcare Professionals

Deferasirox HCP Information Brochure


{pdf_link}

Deferasirox Patient Information Brochure

Deferasirox Patient Information Brochure


{pdf_link}

Deferasirox Physician's Reference Checklist

{healthcare_pro_orange} For Healthcare Professionals

Deferasirox Physician's Reference Checklist


Zentiva

{pdf_link}

Deferasirox HCP Information Brochure

{healthcare_pro_orange} For Healthcare Professionals

Deferasirox HCP Information Brochure


{pdf_link}

Deferasirox Patient Information Brochure

Deferasirox Patient Information Brochure


{pdf_link}

Deferasirox Physician's Reference Checklist

{healthcare_pro_orange} For Healthcare Professionals

Physicians reference checklist for dosing and monitoring


Dr. Reddy's Laboratories (UK) Ltd

{pdf_link}

Deferasirox Important information for patients about your treatment and possible side effects

Please keep this document safe for future reference. This booklet is only intended for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring your treatment is important, and which medicines you can take while on deferasirox.


{pdf_link}

Deferasirox Physicians Reference Checklist.

{healthcare_pro_orange} For Healthcare Professionals

Checklist for dosing and biological monitoring


{pdf_link}

Important Information to Remember About deferasirox Treatment.

{healthcare_pro_orange} For Healthcare Professionals

This booklet provides detailed information on posology and monitoring of patients on deferasirox, to minimise key adverse effects including medication errors during treatment.


Mylan

{pdf_link}

Deferasirox Important information for patients about your treatment and possible side effects

Deferasirox Important information for patients about your treatment and possible side effects


{pdf_link}

Important Information to Remember About Deferasirox Treatment

Important Information to Remember About Deferasirox Treatment


{pdf_link}

Physician’s reference checklist for Deferasirox

Physician’s reference checklist for Deferasirox


MSN Laboratories Europe Ltd

{pdf_link}

Important information for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals

Booklet with detailed information on posology and monitoring of patients on deferasirox, to minimise key adverse effects including medication errors during treatment


{pdf_link}

Important information for Patients

Booklet for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring of your treatment is important, and which medicines you can take while on deferasirox.


{pdf_link}

Physician´s reference checklist

{healthcare_pro_orange} For Healthcare Professionals

Checklist for deferasirox dosing, dose adjustment and biological monitoring.


Glenmark Pharmaceuticals Europe Ltd

{pdf_link}

Important information for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals

minimise key adverse effects including medication errors during treatment


{pdf_link}

Important information for patients about your treatment and possible side effects

Booklet for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring your treatment is important, and which medicines you can take while on deferasirox.


{pdf_link}

Physician’s reference checklist for Deferasirox (deferasirox) dosing and biological monitoring

{healthcare_pro_orange} For Healthcare Professionals

Document highlights important information about requirements for Deferasirox (deferasirox) dosing, dose adjustment and biological monitoring.


Depakote

SANOFI

{pdf_link}

Valproate- “White Box” Warning Labels

{healthcare_pro_orange} For Healthcare Professionals


{pdf_link}

Valproate DHPC for non-dispensing HCPs

{healthcare_pro_orange} For Healthcare Professionals

Direct Healthcare Professional Communication for HCPs (non-dispensing) providing background to the updates to the requirements for oral valproate-containing medicines.


{pdf_link}

Valproate DHPC for Pharmacists

{healthcare_pro_orange} For Healthcare Professionals

Direct Healthcare Professional Communication for pharmacists providing background to the updates to the requirements for oral valproate-containing medicines.


Dexamethasone

Aspen

{pdf_link}

DOSING CARD: Dexamethasone 3.8 mg/ml solution for injection

{healthcare_pro_orange} For Healthcare Professionals

Dosing Card


Dexamfetamine

Brown & Burk UK Ltd

{pdf_link}

Boys 2-18 years growth chart

{healthcare_pro_orange} For Healthcare Professionals

This chart is mainly intended to assess the growth of school age boys. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years, with the WHO growth standard for children aged 2 years to 4 years. The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.


{pdf_link}

Chart for ongoing monitoring during Dexamfetamine sulfate treatment

{healthcare_pro_orange} For Healthcare Professionals

A form template according to prescribing information in more detail, growth, psychiatric and cardiovascular status should be regularly monitored.


{pdf_link}

Dexamfetamine checklist 1

{healthcare_pro_orange} For Healthcare Professionals

Checklist 1: checklist before prescribing Dexamfetamine sulfate 5 mg tablets


{pdf_link}

Dexamfetamine checklist 2

{healthcare_pro_orange} For Healthcare Professionals

Checklist 2: checklist for monitoring of ongoing therapy with Dexamfetamine sulfate 5 mg tablets.


{pdf_link}

Dexamfetamine consideration

{healthcare_pro_orange} For Healthcare Professionals

Consideration when ending treatment with Dexamfetamine sulfate 5mg Tablets


{pdf_link}

Dexamfetamine Pharmacist Information

{healthcare_pro_orange} For Healthcare Professionals

This sheet provides additional information on Dexamfetamine sulfate 5 mg tablets (dexamfetamine sulfate).


{pdf_link}

Dexamfetamine Physician Information

{healthcare_pro_orange} For Healthcare Professionals

A physician’s guide to prescribing Dexamfetamine sulfate 5 mg tablets (dexamfetamine sulfate)


{pdf_link}

Girls UK Growth chart 2-18 years

{healthcare_pro_orange} For Healthcare Professionals

This chart is mainly intended to assess the growth of school age girls. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years, with the WHO growth standard for children aged 2 years to 4 years. The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.


{pdf_link}

Information for parents and carers

Information for parents and carers of patients prescribed with Dexamfetamine sulfate 5 mg tablets (dexamfetamine sulfate)


Sovereign Medical

{pdf_link}

Dexamfetamine Sulfate 5mg tablets

{healthcare_pro_orange} For Healthcare Professionals

Educational materials for Dexamfetamine Sulfate 5mg tablets-PL 06464/3115 These materials have been designed to support you in the appropriate prescription and administration of Dexamfetamine Sulfate 5 mg tablets for the treatment of patients with ADHD. It is recommended that these materials be used in conjunction with the full prescribing information for the product.


Diafer

Pharmacosmos UK Limited

{pdf_link}

HCP Educational Material Ferric Derisomaltose

{healthcare_pro_orange} For Healthcare Professionals

IV iron. Essential Prescription and Administration Information to Minimise the Risk of Serious Hypersensitivity Reactions


{pdf_link}

Patient Educational Material Ferric derisomaltose

Intravenous (IV) Iron. Important Information for Patients about the Possible Risk of Serious Allergic Reactions with IV iron treatment (iron given by injection or infusion into a vein)


Dianette

Bayer plc

{pdf_link}

Dianette Patient Card UK

Dianette patient information card.


{pdf_link}

Dianette Prescriber Checklist UK

{healthcare_pro_orange} For Healthcare Professionals

Dianette - checklist for prescribers.


Disodium pamidronate

Hospira UK Ltd

{pdf_link}

Pamidronate Patient Reminder Card

contains important safety information that patients need to be aware of before and during treatment with pamidronate disodium injections


{pdf_link}

Pamidronate Patient Reminder Card Cover Letter

{healthcare_pro_orange} For Healthcare Professionals

is a letter which should be viewable only by the HCP. It details the requirement for the dispensing pharmacist to discuss the contents of the Patient Reminder Card with the patient prior to dispensing.


Dronedarone

Aurobindo Pharma - Milpharm Ltd.

{pdf_link}

Dronedarone 400 mg film-coated tablets

{healthcare_pro_orange} For Healthcare Professionals

DRONEDARONE PRESCRIBER GUIDE


Aristo Pharma Limited

{pdf_link}

Dronedarone Aristo Prescribers Guide

{healthcare_pro_orange} For Healthcare Professionals

Safety information for the use of Dronedarone Aristo


Drovelis

Gedeon Richter (UK) Ltd

{pdf_link}

Patient Card

Information card for women about the risk of blood clots.


{pdf_link}

Prescriber Checklist

{healthcare_pro_orange} For Healthcare Professionals

Prescriber checklist to be used in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.


Duodopa

AbbVie Ltd

{pdf_link}

Duodopa Best practice patient aftercare

{healthcare_pro_orange} For Healthcare Professionals

This short guide provides advice to healthcare professionals on the management of patients with advanced Parkinson’s disease who have started Duodopa therapy


{pdf_link}

Duodopa Critical Aspects of PEG-J Preparation Placement and Aftercare

{healthcare_pro_orange} For Healthcare Professionals

The information presented in these slides is provided as part of additional Risk Minimisation Program for Duodopa targeted to minimise: –Gastrointestinal (GI) events –Device-related risks –Procedure-related risks associated with the levodopa – carbidopa intestinal gel (LCIG) system


{pdf_link}

Duodopa Patient Pocket Guide

{healthcare_pro_orange} For Healthcare Professionals

This pocket guide provides a practical overview of the Duodopa system and potential complications related to the medication and its delivery system.


{pdf_link}

Duodopa PEG-J aftercare guideline

{healthcare_pro_orange} For Healthcare Professionals

This guide provides advice to healthcare professionals on how to minimise PEG-J tube related complications in patients receiving Duodopa therapy. It should be used in conjunction with any local guidance and the CADD-Legacy 1400 pump instruction manual.


{pdf_link}

Duodopa Safety, PEG-J insertion and aftercare, LCIG System Use and Pump Operations

{healthcare_pro_orange} For Healthcare Professionals

Important Additional Risk Minimisation Information for Healthcare Professionals Training for AbbVie Duodopa Specialists on LCIG System, PEG-J Placement, Aftercare and Minimisation of Procedure Complications


Dyzantil

Aspire Pharma Ltd

{pdf_link}

Valproate - Annual Risk Acknowledgement Form for females GB & NI 2023 - aRMM

Further to the National Patient Safety Alert issued on 28 November 2023, the purpose of this letter is to notify you of an important restriction of indication for new male patients and all female patients aged under 55 years, along with updated contraindications, warnings, and measures to prevent valproate exposure during pregnancy, as well as the availability of revised educational materials to support discussions with patients.


{pdf_link}

Valproate - Annual Risk Acknowledgement Form for males GB & NI 2023 - aRMM

Further to the National Patient Safety Alert issued on 28 November 2023, the purpose of this letter is to notify you of an important restriction of indication for new male patients and all female patients aged under 55 years, along with updated contraindications, warnings, and measures to prevent valproate exposure during pregnancy, as well as the availability of revised educational materials to support discussions with patients.


{pdf_link}

Valproate - Poster-Dispensary-Pregnancy Prevention Programme

{healthcare_pro_orange} For Healthcare Professionals

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme.


{pdf_link}

Valproate- “White Box” Warning Labels

FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products.


{pdf_link}

Valproate- Healthcare professionals (HCPs) Guide Pregnancy prevention programme

{healthcare_pro_orange} For Healthcare Professionals

Educational material for Healthcare Professionals (HCPs) about the Pregnancy Prevention Programme.


{pdf_link}

Valproate- Patient Card-Contraception and Pregnancy Prevention

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme.


{pdf_link}

Valproate- Patient Guide- Pregnancy prevention programme

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme.


You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?